MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has announced the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for products under development.
"We are pleased to be able to add Paul Resnick, M.D. to the executive management team of MabVax," stated President and CEODavid Hansen. "Paul has a strong business and corporate development background with an excellent track record of success. We expect that he will be able to substantially enhance our corporate development efforts as we advance our new generation clinical programs that utilize our HuMab-5B1 antibody platform, including our two Phase I programs, MVT-5873, as therapeutic treatment, and MVT-2163 as a PET imaging agent for pancreatic cancer, and our radioimmunotherapy agent expected to be in Phase 1 clinical trials early next year. All of our programs utilize fully human antibodies from our antibody discovery platform library which identifies natural protective immune responses from vaccination of patients with cancer."